Dana-Farber’s Breast Oncology Center is leading a study for metastatic triple-negative Breast Cancer

Janice Cowden shared a post by Dana-Farber’s Breast Oncology Center on X/Twitter:

“If you, or someone you know, has been diagnosed with metastatic triple-negative breast cancer (TNBC), please share. Patients must be treatment naive in the metastatic setting (1L) and PD-L1-neg. Study of Sacituzumab Govitecan (SG / Trodelvy) with or without Pembrolizumab (Keytruda).”

Quoting Dana-Farber’s Breast Oncology Center’s post:

“Dana-Farber’s Breast Oncology Center is leading a study for metastatic triple-negative Breast Cancer (TNBC) that is PD-L1-negative offering sacituzumab govitecan with or without pembrolizumab. For info call 877-338-7425 or visit here.”

Source: Janice Cowden/X and Dana-Farber’s Breast Oncology Center/X

Janice Cowden is a former nurse, cancer patient and advocate. She was diagnosed with stage I triple-negative early-stage breast cancer in 2011; later, Janice was diagnosed with metastatic disease in 2016. She became a Living Beyond Breast Cancer Hear My Voice (HMV) Advocate in 2017 and continues to serve as a Helpline Volunteer.

Janice works with several patient-founded and -led organizations including PCDI, GRASP, and Project Life MBC. As a trained peer support volunteer, she is founder of an international online peer support group for patients newly diagnosed with MBC. 

he serves on the Board of Directors for METAvivor Research and Support, Inc., and is an Advisory Board member for Project Life MBC. In 2022, she attended ASCO as a patient advocate scholarship recipient. In October 2022, she was invited to serve as a lead patient advocate, representing PCDI, on a research study with ASCO.